{"product_id":"international-myeloma-society-practical-insights-in-and-translational-aspects-of-novel-immune-therapies-in-multiple-myeloma-2025","title":"International Myeloma Society Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma 2025","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos + file sub vtt +  pdf, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: Hematologists, Medical Oncologists, Pathologists, Infectious Disease Specialists, Ophthalmologists, Neurologists, and Immunologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003ch3\u003eAt the conclusion of this educational activity, you will be able to:\u003c\/h3\u003e\n\u003cp\u003eUnderstand the types of patients who should be considered for novel immune based strategies including bispecific T cell engagers and CAR T cell therapy.\u003c\/p\u003e\n\u003cp\u003eUnderstand the differences between TCEs, antibody drug conjugates, and CAR T cell process and data for appropriate care of the patient prior to consideration for these therapies.\u003c\/p\u003e\n\u003cp\u003eUnderstand toxicities and their management post-novel immune strategies.\u003c\/p\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003eAre you a hematologist or oncologist treating patients with multiple myeloma?\u003c\/p\u003e\n\u003cp\u003eIf so, this workshop is for you!\u003c\/p\u003e\n\u003cp\u003eThis high-impact educational program, held in conjunction with the DGHO Annual Meeting, seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals. The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.\u003c\/p\u003e\n\u003cp\u003eBest for Hematologists, Medical Oncologists, Pathologists, Infectious Disease Specialists, Ophthalmologists, Neurologists, and Immunologists.\u003c\/p\u003e\n\u003cp\u003eTopics\u003c\/p\u003e\n\u003cp\u003eAdvances in Diagnostics\u003c\/p\u003e\n\u003cp\u003eBreakout Lesions\/EMD\u003c\/p\u003e\n\u003cp\u003eSingle Cell Spatial Organization of Tumor Microenvironment\u003c\/p\u003e\n\u003cp\u003eAdvances in MRD Detection: Peripheral Blood and Bone Marrow Strategies\u003c\/p\u003e\n\u003cp\u003eMonitoring for Infectious Post-T-Cell-Based Therapy\u003c\/p\u003e\n\u003cp\u003ePredictors of Response and Mechanisms of Relapse\u003c\/p\u003e\n\u003cp\u003eTreatment with Novel Agents\/Novel Combinations\/Novel Concepts\u003c\/p\u003e\n\u003cp\u003eCelMOD (Combinations)\u003c\/p\u003e\n\u003cp\u003e1 Line Therapy with Belamaf + Future Options\u003c\/p\u003e\n\u003cp\u003e2 Line Therapy with Belamaf\/Occular Management\u003c\/p\u003e\n\u003cp\u003eBispecific Combinations\/Trispecifics\u003c\/p\u003e\n\u003cp\u003eCART Cells in Earlier Lines\u003c\/p\u003e\n\u003cp\u003eManagement of Complications\u003c\/p\u003e\n\u003cp\u003eCIDP Post-Cilta-cel\u003c\/p\u003e\n\u003cp\u003eImmune Effector Cell Associated Secondary Malignancies\u003c\/p\u003e\n\u003cp\u003eBridging Therapies\u003c\/p\u003e\n\u003cp\u003eRelapse Management\u003c\/p\u003e\n\u003cp\u003eModulation of the Target Antigen\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405822415044,"sku":null,"price":119.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/International-Myeloma-Society-Practical-Insights-in-and-Translational-Aspects-of-Novel-Immune-Therapies-in-Multiple-Myeloma-2025.jpg?v=1784216676","url":"https:\/\/medicalcoursespro.com\/products\/international-myeloma-society-practical-insights-in-and-translational-aspects-of-novel-immune-therapies-in-multiple-myeloma-2025","provider":"Medicalcoursespro","version":"1.0","type":"link"}